The levels of FAPα in early-stage patients (stage I) were lower than those in healthy controls and higher than those in middle and late stage ESCC patients (stages II, III and IV), but showed no significant difference in either healthy controls or in middle and late stage ESCC (Figure 1B). This evidence concerns the gene FAP and esophageal squamous cell carcinoma.